After AbbVie’s Humira, the best-selling drug in the world, lost patent exclusivity in 2023, company executives placed their bets on two other AbbVie drugs, Skyrizi and Rinvoq, to make up for an anticipated steep decline in revenue.

The two drugs have been on the market since 2019 and treat many of the same conditions as Humira, an immunology drug designed to treat a number of inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.

“We anticipate these two products will collectively exceed the peak revenues achieved by Humira by 2027, with significant growth expected through the end of the decade,” Richard Gonzalez, AbbVie chairman of the board and CEO, said during AbbVie’s full-year 2022 earnings call, Healthcare Brew previously reported.

So, how are Skyrizi and Rinvoq faring so far? Ahead of Abbvie’s execs’ expectations, it turns out.

Keep reading here.—MA

Landing on correct test codes can feel like its own kind of puzzle—one without an answer key. To top it off, healthcare pros now have to learn new ones that correspond with optimized allergy test profiles.

But don’t fret. Get the most up-to-date test codes with the Lab Ordering Guide (LOG) instead. The LOG helps you find the most recent test codes with ease, thanks to features like:

• an easy-to-use process that only requires a zip code
• personalized selections based on patient location and profile
• an inside look at profiles and the allergens included within

Make sure you’re ordering up-to-date test codes and get info on how to interpret ImmunoCAP™ Specific IgE test results.

Snag the most recent test codes.

In one of the biggest moves for Johnson & Johnson since it decided to double down on Johnsons, the pharmaceutical giant has reached an agreement to acquire Proteologix in an $850 million cash deal.

Under the Thursday agreement, J&J would acquire the privately held California-based biotech firm’s developments for atopic dermatitis, which is the most common chronic inflammatory skin disease, according to the National Library of Medicine.

Proteologix’s portfolio includes PX128, an antibody that treats moderate to severe atopic dermatitis (AD) and moderate to severe asthma, which is ready to enter Phase 1 development. The company also created PX130, a drug in preclinical development for moderate to severe AD.

Keep reading here.—CM

The acronym “RRR” most commonly stands for “reduce, reuse, recycle.” But for HR pros, it can also mean “recognition, recovery, renewal.”

Those three words are the basis for the employee well-being strategy at Accenture, Tamarah Duperval-Brownlee, the company’s chief health officer, said at the Workhuman Live conference on April 17.

Duperval-Brownlee, a former doctor, developed the strategy after joining Accenture in July 2021, nearly a year and a half after the Covid-19 pandemic had upended life as many knew it. She said she knew the health crisis would have lasting effects on people’s mental, physical, and financial well-being. This helped inform her well-being strategy and led her to focus on recognition, recovery, and renewal.

“A lot of things happened. We need to acknowledge that they happened. How they showed up needs to be accounted for,” she said.

Keep reading on HR Brew.—MC